Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;15(6):787-790.
doi: 10.1007/s11523-020-00776-0.

SB8: A Bevacizumab Biosimilar

Yahiya Y Syed  1
Affiliations
Review

SB8: A Bevacizumab Biosimilar

Yahiya Y Syed. Target Oncol. 2020 Dec.

Erratum in

Abstract

SB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy volunteers and patients with non-small cell lung cancer (NSCLC). SB8 demonstrated equivalent clinical efficacy to reference bevacizumab in patients with metastatic or recurrent nonsquamous NSCLC, with similar tolerability, safety and immunogenicity profiles.

PubMed Disclaimer

Conflict of interest statement

Yahiya Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Figures

Fig. 1
Fig. 1
Design of the SB8-G31-NSCLC trial [3]. BEV reference bevacizumab, CBP carboplatin, PTX paclitaxel, wk(s) week(s)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. European Medicines Agency. Aybintio 25 mg/ml concentrate for solution for infusion: summary of product characteristics. https://www.ema.europa.eu/ (2020). Accessed 4 Sep 2020.
    1. European Medicines Agency. Aybintio: assessment report. https://www.ema.europa.eu/ (2020). Accessed 4 Sep 2020.
    1. Reck M, Luft A, Bondarenko I, et al. A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. Lung Cancer. 2020;146:12–18. doi: 10.1016/j.lungcan.2020.05.027. - DOI - PubMed
    1. Shin D, Lee YJ, Choi J, et al. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers. Cancer Chemother Pharmacol. 2020;86(4):567–575. doi: 10.1007/s00280-020-04144-7. - DOI - PMC - PubMed
    1. Park D, Kim J, Yun J, et al. Evaluation of the physico-chemical and biological stability of SB8 (Aybintio), a proposed biosimilar to bevacizumab, under ambient and in-use conditions. Adv Ther. 2020 doi: 10.1007/s12325-020-01465-0. - DOI - PubMed

MeSH terms

LinkOut - more resources